JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
Allist Pharmaceuticals, Inc.
Allist Pharmaceuticals, Inc.
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
Memorial Sloan Kettering Cancer Center
University of Washington
RenJi Hospital
University of Kentucky
Sun Yat-sen University
Alliance for Clinical Trials in Oncology
City of Hope Medical Center
M.D. Anderson Cancer Center
Dartmouth-Hitchcock Medical Center
Dartmouth-Hitchcock Medical Center
Cedars-Sinai Medical Center
University Hospital, Ghent
Case Comprehensive Cancer Center
Laval University
National Institutes of Health Clinical Center (CC)
Cybrexa Therapeutics
University of California, Davis
Mercy Medical Center
Revolution Medicines, Inc.
Albert Einstein College of Medicine
Ciusss de L'Est de l'Île de Montréal
University of California, San Diego
Dublin City University
University of Kansas Medical Center
Mercy Medical Center
Ludwig Institute for Cancer Research
Wake Forest University Health Sciences
Wake Forest University Health Sciences
University of Massachusetts, Worcester
University of Utah
Turku University Hospital
Canadian Cancer Trials Group
Catharina Ziekenhuis Eindhoven
Montefiore Medical Center
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Alliance for Clinical Trials in Oncology
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
INSYS Therapeutics Inc
Delcath Systems Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)